ArticleIn vivo (Athens, Greece)
Factors Contributing to Blood Glucose Elevation Associated With Olanzapine Used as an Antiemetic During Cancer Chemotherapy.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThis retrospective study aimed to identify factors contributing to blood glucose elevation associated with olanzapine use and to develop new strategies involving olanzapine aimed at enhancing quality of life in patients undergoing chemotherapy. PATIENTS AND
methodsThis study enrolled 220 cancer patients undergoing chemotherapy between January 2017 and May 2022 at our outpatient chemotherapy center. Variables related to the development of olanzapine-associated blood glucose elevation were extracted from medical records for use in regression analysis. We assessed the severity of blood glucose elevation based on the most recent blood glucose level measured after the final administration of olanzapine. Random blood glucose levels were scored as follows: 0, <140 mg/dl; 1, 140-200 mg/dl; or 2, >200 mg/dl. Multivariate ordered logistic regression analysis was performed to identify potential factors in the development of blood glucose elevations associated with olanzapine.
resultsFactors correlated with olanzapine-associated blood glucose elevation included pre-chemotherapy random blood glucose level (
conclusionIdentifying potential factors contributing to olanzapine-associated blood glucose elevation may assist in developing strategies to improve quality of life for patients undergoing chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.